Global CRO Quintiles has launched a new solution set tailored to meet the needs of emerging biopharmaceutical companies in the Asia-Pacific healthcare market.
"Asia-Pacific is poised to become the world's next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines," said Ross Horsburgh, M.D., senior vice president, head of clinical development, Asia-Pacific, Quintiles. "These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience.”
The Quintiles Asia-Pacific emerging biopharma solution includes:
Dedicated local project leadership based in Asia-Pacific with knowledge of local markets, customs and language
Custom-tailored operational models to meet individual customer priorities and use Quintiles' processes and platforms
Accelerated patient recruitment through Quintiles’ global network of 25 prime and more than 1,200 partner sites, with seven of those prime sites located in Asia-Pacific.
The Asia-Pacific solution gives emerging companies access to Quintiles' data-driven insights, its knowledge of local markets, its in-depth therapeutic and scientific experience and its global drug development platform. It further adds to Quintiles' solutions for emerging companies, which includes Novella Clinical, a specialty CRO focused on the needs of small to mid-sized oncology companies and medical device and diagnostic companies.
Since 2011 Quintiles has worked on more than 60 studies involving almost 20,000 patients for Asia-Pacific emerging companies. Quintiles is the recognized industry leader in the region, having won BioPharma Asia's "Best CRO in Asia" award three times in the event's five-year history, and in 2014—for the sixth time in eight years—named as Asia-Pacific CRO of the Year by Frost & Sullivan, a business research and consulting firm.
